{"id":"https://openalex.org/W2038834880","doi":"https://doi.org/10.1016/s0924-977x(02)80691-5","title":"Behavioural profile of L-741,741, a selective D4 dopamine receptor antagonist, in social encounters between male mice","display_name":"Behavioural profile of L-741,741, a selective D4 dopamine receptor antagonist, in social encounters between male mice","publication_year":2002,"publication_date":"2002-10-01","ids":{"openalex":"https://openalex.org/W2038834880","doi":"https://doi.org/10.1016/s0924-977x(02)80691-5","mag":"2038834880"},"language":"en","primary_location":{"id":"doi:10.1016/s0924-977x(02)80691-5","doi":"https://doi.org/10.1016/s0924-977x(02)80691-5","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0924-977x(02)80691-5","pdf_url":null,"source":{"id":"https://openalex.org/S168041952","display_name":"European Neuropsychopharmacology","issn_l":"0924-977X","issn":["0924-977X","1873-7862"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Neuropsychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040512555","display_name":"Gema Luna","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Luna","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050856085","display_name":"Carmen Pedraza","orcid":"https://orcid.org/0000-0002-0011-2817","observed_orcids":["https://orcid.org/0000-0002-0011-2817"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Pedraza","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000209760","display_name":"Estrella Bur\u00f3n","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Bur\u00f3n","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"F. Garc\u00eda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Garc\u00eda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5063573432","display_name":"Jos\u00e9 Francisco Navarro","orcid":"https://orcid.org/0000-0002-5104-8974","observed_orcids":["https://orcid.org/0000-0002-5104-8974"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J.F. Navarro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.10354547,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"12","issue":null,"first_page":"405","last_page":"405"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11541","display_name":"Neuroendocrine regulation and behavior","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2807","display_name":"Endocrine and Autonomic Systems"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/social-behavior","display_name":"social behavior","score":0.36500000953674316},{"id":"https://openalex.org/keywords/agonistic-behavior","display_name":"agonistic behavior","score":0.7770000100135803},{"id":"https://openalex.org/keywords/aggression","display_name":"aggression","score":0.7070000171661377},{"id":"https://openalex.org/keywords/morphine","display_name":"morphine","score":0.8149999976158142},{"id":"https://openalex.org/keywords/haloperidol","display_name":"haloperidol","score":0.9990000128746033},{"id":"https://openalex.org/keywords/opioid-dopamine-interaction","display_name":"opioid-dopamine interaction","score":0.9629999995231628},{"id":"https://openalex.org/keywords/motor-activity","display_name":"motor activity","score":0.8560000061988831},{"id":"https://openalex.org/keywords/male-mice","display_name":"male mice","score":0.5139999985694885},{"id":"https://openalex.org/keywords/antipsychotic-effects","display_name":"antipsychotic effects","score":0.5830000042915344}],"concepts":[{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.9053843021392822},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.8034493923187256},{"id":"https://openalex.org/C2777389121","wikidata":"https://www.wikidata.org/wiki/Q81225","display_name":"Morphine","level":2,"score":0.6982964873313904},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.6368951797485352},{"id":"https://openalex.org/C187898756","wikidata":"https://www.wikidata.org/wiki/Q395324","display_name":"Agonistic behaviour","level":3,"score":0.6156758666038513},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.5781130194664001},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5723609924316406},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.5621863603591919},{"id":"https://openalex.org/C2779448149","wikidata":"https://www.wikidata.org/wiki/Q191797","display_name":"Aggression","level":2,"score":0.5518782138824463},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5319281816482544},{"id":"https://openalex.org/C120069818","wikidata":"https://www.wikidata.org/wiki/Q415496","display_name":"Dopamine receptor","level":3,"score":0.4770997166633606},{"id":"https://openalex.org/C2775962371","wikidata":"https://www.wikidata.org/wiki/Q908096","display_name":"Opioid antagonist","level":5,"score":0.46054476499557495},{"id":"https://openalex.org/C2779886867","wikidata":"https://www.wikidata.org/wiki/Q421797","display_name":"Opioid receptor","level":4,"score":0.4423506557941437},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.32626140117645264},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3174048066139221},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.2959252893924713},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.27446264028549194},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2688482701778412},{"id":"https://openalex.org/C2778750930","wikidata":"https://www.wikidata.org/wiki/Q4540629","display_name":"(+)-Naloxone","level":4,"score":0.19868579506874084},{"id":"https://openalex.org/C138496976","wikidata":"https://www.wikidata.org/wiki/Q175002","display_name":"Developmental psychology","level":1,"score":0.18621918559074402}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s0924-977x(02)80691-5","doi":"https://doi.org/10.1016/s0924-977x(02)80691-5","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0924-977x(02)80691-5","pdf_url":null,"source":{"id":"https://openalex.org/S168041952","display_name":"European Neuropsychopharmacology","issn_l":"0924-977X","issn":["0924-977X","1873-7862"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Neuropsychopharmacology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9074000120162964,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2026725691","https://openalex.org/W1994700580","https://openalex.org/W2382173714","https://openalex.org/W2046140045","https://openalex.org/W2086788186","https://openalex.org/W2069494262","https://openalex.org/W7018491575","https://openalex.org/W2090546663","https://openalex.org/W2064467934","https://openalex.org/W2017224092"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}